Literature DB >> 25967542

Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders.

Elaine Niven1, Judith Newton, Jennifer Foley, Shuna Colville, Robert Swingler, Siddharthan Chandran, Thomas H Bak, Sharon Abrahams.   

Abstract

Our objective was to assess the validity of the Edinburgh Cognitive and Behaviour ALS Screen (ECAS), a multi-domain screen designed to detect cognitive deficits in patients with motor disorders. Forty ALS patients (without pre-diagnosed dementia) and 40, age-, gender- and education-matched healthy controls were recruited. All participants underwent extensive neuropsychological assessment and the ECAS. Performance at neuropsychological assessment across five domains (fluency, executive function, language, memory and visuospatial function) was compared to the ECAS ALS-Specific (fluency, executive functions and social cognition, language), ALS Non-specific (memory, visuospatial functions), and Total scores. Data from the healthy controls produced population-based abnormality cut-offs: composite score performance ≤ 2 SD in any domain classified impairment at neuropsychological assessment. Thirty-three percent of patients were impaired, most commonly in a single domain (executive or language dysfunction). Receiver Operator Curve (ROC) analyses using ECAS Total scores and ALS-Specific scores revealed 85% sensitivity and 85% specificity in the detection of cognitive impairment characteristic of ALS (fluency, executive function, language). A five-point borderline range produced optimal values (ALS-Specific Score 77-82, and ECAS-Total Score 105-110). In conclusion, validation against gold standard extensive neuropsychology demonstrated that the ECAS is a screening tool with high sensitivity and specificity to impairment characteristic of ALS.

Entities:  

Keywords:  Cognition; executive functions; fluency; language; screen

Mesh:

Year:  2015        PMID: 25967542     DOI: 10.3109/21678421.2015.1030430

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  35 in total

1.  Caregivers of patients with amyotrophic lateral sclerosis: investigating quality of life, caregiver burden, service engagement, and patient survival.

Authors:  Tom Burke; Miriam Galvin; Marta Pinto-Grau; Katie Lonergan; Caoifa Madden; Iain Mays; Sile Carney; Orla Hardiman; Niall Pender
Journal:  J Neurol       Date:  2017-03-09       Impact factor: 4.849

2.  Edinburgh Cognitive and Behavioural ALS Screen (ECAS)-Italian version: regression based norms and equivalent scores.

Authors:  Mattia Siciliano; Luigi Trojano; Francesca Trojsi; Roberta Greco; Manuela Santoro; Giuseppe Basile; Fausta Piscopo; Alfonsina D'Iorio; Manila Patrone; Cinzia Femiano; Mariarosaria Monsurrò; Gioacchino Tedeschi; Gabriella Santangelo
Journal:  Neurol Sci       Date:  2017-03-22       Impact factor: 3.307

Review 3.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.

Authors:  Michael J Strong; Sharon Abrahams; Laura H Goldstein; Susan Woolley; Paula Mclaughlin; Julie Snowden; Eneida Mioshi; Angie Roberts-South; Michael Benatar; Tibor HortobáGyi; Jeffrey Rosenfeld; Vincenzo Silani; Paul G Ince; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-01-05       Impact factor: 4.092

4.  Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).

Authors:  Christopher Crockford; Judith Newton; Katie Lonergan; Caoifa Madden; Iain Mays; Meabhdh O'Sullivan; Emmet Costello; Marta Pinto-Grau; Alice Vajda; Mark Heverin; Niall Pender; Ammar Al-Chalabi; Orla Hardiman; Sharon Abrahams
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-12-07       Impact factor: 4.092

5.  Neuroanatomical associations of the Edinburgh cognitive and Behavioural ALS screen (ECAS).

Authors:  Sneha Chenji; Abdullah Ishaque; Dennell Mah; Esther Fujiwara; Christian Beaulieu; Peter Seres; Simon J Graham; Richard Frayne; Lorne Zinman; Angela Genge; Lawrence Korngut; Wendy Johnston; Sanjay Kalra
Journal:  Brain Imaging Behav       Date:  2021-06       Impact factor: 3.978

6.  Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis.

Authors:  Jordi A Matías-Guiu; Vanesa Pytel; María Nieves Cabrera-Martín; Lucía Galán; María Valles-Salgado; Antonio Guerrero; Teresa Moreno-Ramos; Jorge Matías-Guiu; José Luis Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-04       Impact factor: 9.236

7.  Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum.

Authors:  Smriti Agarwal; Elizabeth Highton-Williamson; Jashelle Caga; José M Matamala; Thanuja Dharmadasa; James Howells; Margaret C Zoing; Kazumoto Shibuya; Nimeshan Geevasinga; Steve Vucic; John R Hodges; Rebekah M Ahmed; Matthew C Kiernan
Journal:  J Neurol       Date:  2018-06-04       Impact factor: 4.849

8.  Screening for cognition in amyotrophic lateral sclerosis: test characteristics of a new screen.

Authors:  Emma Beeldman; Rosanne Govaarts; Marianne de Visser; Michael A van Es; Yolande A L Pijnenburg; Ben A Schmand; Joost Raaphorst
Journal:  J Neurol       Date:  2021-02-06       Impact factor: 4.849

9.  Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum.

Authors:  Ignacio Illán-Gala; Victor Montal; Jordi Pegueroles; Eduard Vilaplana; Daniel Alcolea; Oriol Dols-Icardo; Noemi de Luna; Janina Turón-Sans; Elena Cortés-Vicente; Luis Martinez-Roman; Maria Belén Sánchez-Saudinós; Andrea Subirana; Laura Videla; Isabel Sala; Isabel Barroeta; Sílvia Valldeneu; Rafael Blesa; Jordi Clarimón; Alberto Lleó; Juan Fortea; Ricard Rojas-García
Journal:  Neurology       Date:  2020-09-10       Impact factor: 9.910

10.  Automated analysis of natural speech in amyotrophic lateral sclerosis spectrum disorders.

Authors:  Naomi Nevler; Sharon Ash; Corey McMillan; Lauren Elman; Leo McCluskey; David J Irwin; Sunghye Cho; Mark Liberman; Murray Grossman
Journal:  Neurology       Date:  2020-07-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.